Results 11 to 20 of about 175,837 (263)

Advances in the treatment of melanoma [PDF]

Clinical Medicine, 2012
#### Key Points Melanoma incidence and mortality are increasing Melanoma is relatively resistant to therapy with standard chemotherapeutic regimens The small molecule inhibitor vemurafenib that targets melanomas with a common and specific mutation (BRAF V600E) has shown promise in the ...
Lacy, Katie E., Karagiannis, Sophia N., Nestle, Frank O.   +2 more
openaire   +3 more sources

OUR EXPERIENCE WITH DACARBAZINE IN THE TREATMENT OF PATIENTS WITH INOPERABLE SKIN MELANOMA [PDF]

Journal of IMAB, 2016
Objective: The standard treatment for inoperable skin melanoma is chemotherapy. The aim of this study was to explore the efficacy and safety of therapy with dacarbazine in patients with advanced melanoma.
Deyan Davidov
doaj   +1 more source

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain

Translational Oncology, 2020
Real-world data on BRAF mutation frequency in advanced melanoma are lacking in Spain. Moreover, data available on clinicopathological profile of patients with advanced BRAF-mutant melanoma are currently limited.
Jose A. Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, Javier Hernández-Losa, Lucía Alós Hernández, Pablo Cerezuela Fuentes, Sebastián Ortiz Reina, Eugenia Ortega Izquierdo, Rosa M Martí, Jesús Soberino García, Berta Ferrer Fábrega, José Luis Rodríguez Peralto   +11 more
doaj   +1 more source

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations

Frontiers in Oncology, 2023
The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the
Lucía Vázquez-Montero, María del Carmen Álamo de la Gala, Luis de la Cruz-Merino, Luis de la Cruz-Merino, Luis de la Cruz-Merino   +4 more
doaj   +1 more source

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment

JACC: Case Reports, 2019
Malignant melanoma demonstrates the highest rate of cardiac metastases. The incidence of melanoma is rising. The prognosis of people with advanced melanoma is generally poor.
Frederik Uttenthal Larsen, MD, Johannes Katate Wilhjelm, MD, Eric Steen Nielsen, MD   +2 more
doaj   +1 more source

Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study

Biomedicines, 2022
Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while ...
Daniella Kuzmanovszki, Norbert Kiss, Béla Tóth, Tünde Kerner, Veronika Tóth, József Szakonyi, Kende Lőrincz, Judit Hársing, Eleonóra Imrédi, Alexa Pfund, Ákos Szabó, Valentin Brodszky, Fanni Rencz, Péter Holló   +13 more
doaj   +1 more source

Advances in management of melanoma [PDF]

Australian and New Zealand Journal of Medicine, 1999
It is clear from the above that the sentinel node technique and assessment of circulating melanoma cells has provided important additional methods for staging and assessment of prognosis of patients with melanoma. Cure of the disease still depends on good quality surgery and implementation of quality control measures to ensure the adequacy of surgical ...
openaire   +2 more sources

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection

Frontiers in Medicine, 2019
Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melanoma ...
Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Ryo Amagai, Akira Hashimoto, Takanori Hidaka, Setsuya Aiba   +7 more
doaj   +1 more source

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

Frontiers in Oncology, 2018
Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma.
Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Naoko Wada, Hiroyuki Irie, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba   +21 more
doaj   +1 more source

Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma

Frontiers in Oncology, 2023
IntroductionCombined immune checkpoint inhibition (ICI) with ipilimumab and nivolumab is a widely used treatment regimen for metastatic melanoma with non-resectable metastases.
Charlotte Nübel, Teresa Amaral, Ulrike Leiter, Lukas Flatz, Andrea Forschner   +4 more
doaj   +1 more source